UPCC 05817: A Phase II Trial of Nivolumab plus Ipilimumab in Men with Metastatic Castration Resistant Prostate Cancer

UPCC 05817: A Phase II Trial of Nivolumab plus Ipilimumab in Men with Metastatic Castration Resistant Prostate Cancer
99 years or below
All
Phase 2
1 Location

Brief description of study

The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of a combination of two investigational drugs called nivolumab (also known as BMS-936558) and ipilimumab (BMS-734016) in subjects with advanced prostate cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD, tbd, tbd
  • Age: 99 years or below
  • Gender: All
Updated on 27 Aug 2018. Study ID: 827419

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.